RenovaCare (RenovaCare) Change In Working Capital

: $0.48 Mil (TTM As of Sep. 2022)

View and export this data going back to . Start your Free Trial

RenovaCare's change in working capital for the quarter that ended in Sep. 2022 was $-0.06 Mil.

RenovaCare's change in working capital for the fiscal year that ended in Dec. 2021 was $0.07 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

RenovaCare Change In Working Capital Historical Data

The historical data trend for RenovaCare's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovaCare Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Working Capital

Get a 7-Day Free Trial

0.19

-0.14

-0.05

0.62

0.07

RenovaCare Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Working Capital	Get a 7-Day Free Trial															0.51	0.54	-0.28	0.28	-0.06

RenovaCare Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.48 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

RenovaCare Change In Working Capital Related Terms

Thank you for viewing the detailed overview of RenovaCare's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

RenovaCare (RenovaCare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovaCare Inc (OTCPK:RCAR) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260

Website

https://www.renovacareinc.com

RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.

Executives

Patsy Trisler	officer: Vice President	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Thomas Bold	officer: President & CEO	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Joseph Sierchio	director	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Kenneth Kirkland	director	430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Rhonda Beth Rosen	director, officer: President & CEO	43 DICKINSON ROAD, BASKING RIDGE NJ 07920
1420525 Alberta Ltd.	10 percent owner	1628 WEST 1ST AVENUE, SUITE 216, VANCOUVER A1 V6J1G1
David E Jenkins	director	406 NORTH HERMOSA DRIVE, PALM SPRINGS CA 92262
Antonino G Cacace	director, officer: President	CRUD-Y-GWYNT, CASWELL BAY, SWANSEA X0 SA3 3BU
Jeet Sidhu	director	5667 SUNRISE CRESCENT WEST, SURREY, BC A1 V3S 7M4
Derek Cooper	officer: President/ CEO
Frank J Fabio	officer: CFO/Sec.(Resigned 1/9/2009)	670 BROADWAY, MASSAPEQUA NY 11758
Christian F Hudson	director	33 CHURCHILL ROAD, TENAFLY NJ 07670
Harmel S Rayat	director, 10 percent owner	700 - 688 WEST HASTINGS STREET, VANCOUVER A1 V6B 1P1
Stanley Wong	officer: President/CEO
Terri Dumoulin	director, officer: Secretary/Treasurer